Pharvaris N.V. (PHVS) Stock Analysis

What Pharvaris N.V. does

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Key metrics

ETFs linked to PHVS

Broad-market and Healthcare sector ETFs an investor holding Pharvaris N.V. is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PHVS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Pharvaris N.V.?

Pharvaris N.V. trades under the ticker PHVS on NASDAQ.

Which exchange is PHVS listed on?

PHVS is listed on NASDAQ.

What sector does Pharvaris N.V. operate in?

Pharvaris N.V. is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PHVS in a portfolio?

PortView shows PHVS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.